A pharmacokinetic study of homoharringtonine (omacetaxine mepesuccinate) administered subcutaneously to patients with advanced solid and hematologic tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Omacetaxine mepesuccinate (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors ChemGenex Pharmaceuticals
- 07 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 03 Jun 2008 New trial record.